Human Engineered Cardiac Tissues Created Using Induced Pluripotent Stem Cells Reveal Functional Characteristics of BRAF-Mediated Hypertrophic Cardiomyopathy
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Hypertrophic cardiomyopathy (HCM) is a leading cause of sudden cardiac death that often goes undetected in the general population. HCM is also prevalent in patients with cardio-facio-cutaneous syndrome (CFCS), which is a genetic disorder characterized by aberrant signaling in the RAS/MAPK signaling cascade. Understanding the mechanisms of HCM development in such RASopathies may lead to novel therapeutic strategies, but relevant experimental models of the human condition are lacking. Therefore, the objective of this study was to develop the first 3D human engineered cardiac tissue (hECT) model of HCM. The hECTs were created using human cardiomyocytes obtained by directed differentiation of induced pluripotent stem cells derived from a patient with CFCS due to an activating BRAF mutation. The mutant myocytes were directly conjugated at a 3:1 ratio with a stromal cell population to create a tissue of defined composition. Compared to healthy patient control hECTs, BRAF-hECTs displayed a hypertrophic phenotype by culture day 6, with significantly increased tissue size, twitch force, and atrial natriuretic peptide (ANP) gene expression. Twitch characteristics reflected increased contraction and relaxation rates and shorter twitch duration in BRAF-hECTs, which also had a significantly higher maximum capture rate and lower excitation threshold during electrical pacing, consistent with a more arrhythmogenic substrate. By culture day 11, twitch force was no longer different between BRAF and wild-type hECTs, revealing a temporal aspect of disease modeling with tissue engineering. Principal component analysis identified diastolic force as a key factor that changed from day 6 to day 11, supported by a higher passive stiffness in day 11 BRAF-hECTs. In summary, human engineered cardiac tissues created from BRAF mutant cells recapitulated, for the first time, key aspects of the HCM phenotype, offering a new in vitro model for studying intrinsic mechanisms and screening new therapeutic approaches for this lethal form of heart disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In contrast to prior cardiac disease modeling approaches focused on genetic mutations, 20,42,43 this study demonstrates the use of biologics for induction of disease without requiring patient-specific human induced pluripotent stem cells.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdi, H., & Williams, L. J. (2010) · WIREs Computational Statistics · doi:10.1002/wics.101 · Cited by 11,104
What is principal component analysis?
Ringnér, M. (2008) · Nature Biotechnology · doi:10.1038/nbt0308-303 · Cited by 2,407
Biowire: a platform for maturation of human pluripotent stem cell–derived cardiomyocytes
Nunes, S. S., Miklas, J. W., Liu, J., Aschar-Sobbi, R., Xiao, Y., Zhang, B., Jiang, J., Massé, S., Gagliardi, M., Hsieh, A., et al. (2013) · Nature Methods · doi:10.1038/nmeth.2524 · Cited by 952
Rauen, K. A. (2013) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-091212-153523 · Cited by 879 · cited 3×
“The altered twitch dynamics between control and mutant tissues played a dominant role in distinguishing tissue types at both time points, which may reflect a functional consequence of the dysregulated calcium handling observed in HCM [2,39] and Ras activation [40,41] and also observed in the purified BRAF-mutant cells…”
BackgroundWang, G., McCain, M. L., Yang, L., He, A., Pasqualini, F. S., Agarwal, A., Yuan, H., Jiang, D., Zhang, D., Zangi, L., et al. (2014) · Nature Medicine · doi:10.1038/nm.3545 · Cited by 837
The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice
Bueno, O. F. (2000) · The EMBO Journal · doi:10.1093/emboj/19.23.6341 · Cited by 774
Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy
Wilkins, B. J., Dai, Y.-S., Bueno, O. F., Parsons, S. A., Xu, J., Plank, D. M., Jones, F., Kimball, T. R., & Molkentin, J. D. (2004) · Circulation Research · doi:10.1161/01.res.0000109415.17511.18 · Cited by 761 · cited 1×
“The altered twitch dynamics between control and mutant tissues played a dominant role in distinguishing tissue types at both time points, which may reflect a functional consequence of the dysregulated calcium handling observed in HCM [2,39] and Ras activation [40,41] and also observed in the purified BRAF-mutant cells…”
BackgroundMummery, C. L., Zhang, J., Ng, E. S., Elliott, D. A., Elefanty, A. G., & Kamp, T. J. (2012) · Circulation Research · doi:10.1161/circresaha.110.227512 · Cited by 713
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
Carvajal-Vergara, X., Sevilla, A., D’Souza, S. L., Ang, Y.-S., Schaniel, C., Lee, D.-F., Yang, L., Kaplan, A. D., Adler, E. D., Rozov, R., et al. (2010) · Nature · doi:10.1038/nature09005 · Cited by 690 · cited 6×
“Recently, cardiac myocytes were derived from the induced pluripotent stem cells (iPSCs) of a patient with Noonan syndrome with multiple lentigines (formerly, LEOPARD syndrome) and found to be intrinsically hypertrophic [8].”
BackgroundMethodResultInfluentialSelf-citationGrowth of engineered human myocardium with mechanical loading and vascular coculture
Tulloch, N. L., Muskheli, V., Razumova, M. V., Korte, F. S., Regnier, M., Hauch, K. D., Pabon, L., Reinecke, H., & Murry, C. E. (2011) · Circulation Research · doi:10.1161/circresaha.110.237206 · Cited by 666 · cited 1×
“papers have described hECTs created from human iPSCs [31,32,34,35].”
BackgroundMaron, B. J., Ommen, S. R., Semsarian, C., Spirito, P., Olivotto, I., & Maron, M. S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.003 · Cited by 652 · cited 1×
“Most patients will develop some degree of obstructive disease that can lead to heart failure, while others experience arrhythmias and sudden cardiac death [5].”
BackgroundDubois, N. C., Craft, A. M., Sharma, P., Elliott, D. A., Stanley, E. G., Elefanty, A. G., Gramolini, A., & Keller, G. (2011) · Nature Biotechnology · doi:10.1038/nbt.2005 · Cited by 544 · cited 1×
“To address the inconsistent efficiency of differentiating hiPSCs to cardiomyocytes the entire differentiation population was sorted based on SIRPα, a surface marker of cardiomyocytes [28], and THY-1/CD90, a cardiac stromal cell marker [29], and recombined in a 3:1 ratio of SIRPα:CD90 cells that were incubated for 48 h…”
MethodMAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets
Muslin, A. J. (2008) · Clinical Science · doi:10.1042/cs20070430 · Cited by 494
Cardiac Tissue Engineering: State of the Art
Hirt, M. N., Hansen, A., & Eschenhagen, T. (2014) · Circulation Research · doi:10.1161/circresaha.114.300522 · Cited by 425 · cited 3×
“The primers used were cardiac troponin (cTnT), atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and sarcoplasmic/endoplasmic reticulum calcium PLOSONE | DOI:10.1371/journal.pone.0146697 January 19, 2016 5 / 17 ATPase 2 (SERCA2a).”
BackgroundInfluentialHuman engineered heart tissue as a versatile tool in basic research and preclinical toxicology
Schaaf, S., Shibamiya, A., Mewe, M., Eder, A., Stöhr, A., Hirt, M. N., Rau, T., Zimmermann, W.-H., Conradi, L., Eschenhagen, T., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026397 · Cited by 365 · cited 1×
“The time-to-next peak and time-to-previous peak for each contraction was measured and plotted against one another to form a cloud of points that represent the variability of the spontaneous rate, similar to methods reported previously [25].”
ResultMitogen-Activated Protein Kinases in Heart Development and Diseases
Wang, Y. (2007) · Circulation · doi:10.1161/circulationaha.106.679589 · Cited by 315
Sarkozy, A., Carta, C., Moretti, S., Zampino, G., Digilio, M. C., Pantaleoni, F., Scioletti, A. P., Esposito, G., Cordeddu, V., Lepri, F., et al. (2009) · Human Mutation · doi:10.1002/humu.20955 · Cited by 303
Self-citationDesign and formulation of functional pluripotent stem cell-derived cardiac microtissues
Thavandiran, N., Dubois, N., Mikryukov, A., Massé, S., Beca, B., Simmons, C. A., Deshpande, V. S., McGarry, J. P., Chen, C. S., Nanthakumar, K., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311120110 · Cited by 285
The cardiofaciocutaneous syndrome
Roberts, A., Allanson, J., Jadico, S. K., Kavamura, M. I., Noonan, J., Opitz, J. M., Young, T., & Neri, G. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.042796 · Cited by 271 · cited 10×
“Human iPSCs were created from patients with the T599R activating BRAFmutation [21], a rare [22], but severe [23] form of CFCS, via retroviral-based methods previously reported but with some modification [8].”
BackgroundInfluentialAdvancing functional engineered cardiac tissues toward a preclinical model of human myocardium
Turnbull, I. C., Karakikes, I., Serrao, G. W., Backeris, P., Lee, J., Xie, C., Senyei, G., Gordon, R. E., Li, R. A., Akar, F. G., et al. (2014) · The FASEB Journal · doi:10.1096/fj.13-228007 · Cited by 184
Self-citationPhenotypic diversity in hypertrophic cardiomyopathy
Arad, M. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.20.2499 · Cited by 183 · cited 1×
“It is a pathological cardiac disorder with no distinct precipitating insult, usually associated with a variety of genes encoding sarcomeric components [1].”
BackgroundIncreased afterload induces pathological cardiac hypertrophy: a new in vitro model
Hirt, M. N., Sörensen, N. A., Bartholdt, L. M., Boeddinghaus, J., Schaaf, S., Eder, A., Vollert, I., Stöhr, A., Schulze, T., Witten, A., et al. (2012) · Basic Research in Cardiology · doi:10.1007/s00395-012-0307-z · Cited by 154
Genetics of hypertrophic cardiomyopathy
Konno, T., Chang, S., Seidman, J. G., & Seidman, C. E. (2010) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e3283375698 · Cited by 139 · cited 2×
“The altered twitch dynamics between control and mutant tissues played a dominant role in distinguishing tissue types at both time points, which may reflect a functional consequence of the dysregulated calcium handling observed in HCM [2,39] and Ras activation [40,41] and also observed in the purified BRAF-mutant cells…”
BackgroundNeurological complications of cardio‐facio‐cutaneous syndrome
Yoon, G., Rosenberg, J., Blaser, S., & Rauen, K. A. (2007) · Developmental Medicine & Child Neurology · doi:10.1111/j.1469-8749.2007.00894.x · Cited by 127 · cited 1×
“Human iPSCs were created from patients with the T599R activating BRAFmutation [21], a rare [22], but severe [23] form of CFCS, via retroviral-based methods previously reported but with some modification [8].”
MethodArmour, C. M., & Allanson, J. E. (2008) · Journal of Medical Genetics · doi:10.1136/jmg.2007.054460 · Cited by 122 · cited 1×
“Cardiac abnormalities are among the most common findings in CFCS [18], including HCM in approximately 40% of patients [19].”
BackgroundThree-dimensional filamentous human diseased cardiac tissue model
Ma, Z., Koo, S., Finnegan, M. A., Loskill, P., Huebsch, N., Marks, N. C., Conklin, B. R., Grigoropoulos, C. P., & Healy, K. E. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2013.10.052 · Cited by 113 · cited 2×
“papers have described hECTs created from human iPSCs [31,32,34,35].”
BackgroundCardio‐facio‐cutaneous syndrome: Does genotype predict phenotype?
Allanson, J. E., Annerén, G., Aoki, Y., Armour, C. M., Bondeson, M., Cave, H., Gripp, K. W., Kerr, B., Nystrom, A., Sol‐Church, K., et al. (2011) · American Journal of Medical Genetics Part C: Seminars in Medical Genetics · doi:10.1002/ajmg.c.30295 · Cited by 94 · cited 1×
“CFCS patients with BRAFmutations have a higher prevalence of HCM versus the less commonMEKmutations [20].”
BackgroundUrotensin II Promotes Hypertrophy of Cardiac Myocytes via Mitogen-Activated Protein Kinases
Onan, D., Pipolo, L., Yang, E., Hannan, R. D., & Thomas, W. G. (2004) · Molecular Endocrinology · doi:10.1210/me.2003-0309 · Cited by 90
Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart
Zheng, M., Dilly, K., Dos Santos Cruz, J., Li, M., Gu, Y., Ursitti, J. A., Chen, J., Ross, J., Chien, K. R., Lederer, J. W., et al. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00110.2003 · Cited by 90 · cited 1×
“The altered twitch dynamics between control and mutant tissues played a dominant role in distinguishing tissue types at both time points, which may reflect a functional consequence of the dysregulated calcium handling observed in HCM [2,39] and Ras activation [40,41] and also observed in the purified BRAF-mutant cells…”
Backgroundde Lange, W. J., Hegge, L. F., Grimes, A. C., Tong, C. W., Brost, T. M., Moss, R. L., & Ralphe, J. C. (2011) · Circulation Research · doi:10.1161/circresaha.111.242354 · Cited by 70
Wang, J., Chen, A., Lieu, D. K., Karakikes, I., Chen, G., Keung, W., Chan, C. W., Hajjar, R. J., Costa, K. D., Khine, M., et al. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.07.039 · Cited by 69 · cited 1×
“Further electrophysiological testing using a programmed electrical stimulation protocol [30] may be required to assess the true arrhythmogenic potential of hECTs.”
MethodSelf-citationThree-dimensional functional human myocardial tissues fabricated from induced pluripotent stem cells
Komae, H., Sekine, H., Dobashi, I., Matsuura, K., Ōno, M., Okano, T., & Shimizu, T. (2015) · Journal of Tissue Engineering and Regenerative Medicine · doi:10.1002/term.1995 · Cited by 62 · cited 1×
“papers have described hECTs created from human iPSCs [31,32,34,35].”
BackgroundDistinct Molecular Phenotypes in Murine Cardiac Muscle Development, Growth, and Hypertrophy
Schoenfeld, J., Vasser, M., Jhurani, P., Ng, P., Hunter, J. J., Ross, J., Chien, K. R., & Lowe, D. G. (1998) · Journal of Molecular and Cellular Cardiology · doi:10.1006/jmcc.1998.0787 · Cited by 58 · cited 1×
“Molecularly, HCM is characterized by enhanced expression of hypertrophic markers and aberrant calcium handling [2,3].”
BackgroundMyocyte-Depleted Engineered Cardiac Tissues Support Therapeutic Potential of Mesenchymal Stem Cells
Serrao, G. W., Turnbull, I. C., Ancukiewicz, D., Kim, D. E., Kao, E., Cashman, T. J., Hadri, L., Hajjar, R. J., & Costa, K. D. (2012) · Tissue Engineering Part A · doi:10.1089/ten.tea.2011.0278 · Cited by 54 · cited 4×
“The cell tissue mixture was pipetted into a custom polydimethylsiloxane (PDMS) mold with 100 μl (10(6) cells/well) of tissue mix and incubated at 37°C in 5% CO2 for two hours to promote tissue compaction and gelling as described previously [9,24].”
MethodInfluentialSelf-citationSignaling to Cardiac Hypertrophy: Insights from Human and Mouse RASopathies
Sala, V., Gallo, S., Leo, C., Gatti, S., Gelb, B. D., & Crepaldi, T. (2012) · Molecular Medicine · doi:10.2119/molmed.2011.00512 · Cited by 53 · cited 2×
“Congenital cardiac abnormalities, including HCM, are present in many of the RASopathies and may be due to the effect of abnormal RAS signaling in multiple populations of cardiac cell progenitors [12].”
BackgroundSelf-citationGago‐López, N., Awaji, O., Zhang, Y., Ko, C. Y., Nsair, A., Liem, D. A., Stempien‐Otero, A., & MacLellan, W. R. (2014) · Stem Cell Reports · doi:10.1016/j.stemcr.2014.03.003 · Cited by 51 · cited 1×
“To address the inconsistent efficiency of differentiating hiPSCs to cardiomyocytes the entire differentiation population was sorted based on SIRPα, a surface marker of cardiomyocytes [28], and THY-1/CD90, a cardiac stromal cell marker [29], and recombined in a 3:1 ratio of SIRPα:CD90 cells that were incubated for 48 h…”
MethodGiα1-Mediated Cardiac Electrophysiological Remodeling and Arrhythmia in Hypertrophic Cardiomyopathy
Ruan, H., Mitchell, S., Vainoriene, M., Lou, Q., Xie, L., Ren, S. V., Goldhaber, J. I., & Wang, Y. (2007) · Circulation · doi:10.1161/circulationaha.106.682773 · Cited by 43
Rodriguez‐Viciana, P., & Rauen, K. A. (2008) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(07)38019-1 · Cited by 34
Experimental models of inherited cardiomyopathy and its therapeutics
Nonaka, M., & Morimoto, S. (2014) · World Journal of Cardiology · doi:10.4330/wjc.v6.i12.1245 · Cited by 21 · cited 1×
“Animal models for HCM have been invaluable in developing an understanding of the mechanisms governing the development of the disease [6,7].”
BackgroundGenetic engineering of somatic cells to study and improve cardiac function
Kirkton, R. D., & Bursac, N. (2012) · EP Europace · doi:10.1093/europace/eus269 · Cited by 16 · cited 1×
“Other studies have found that conduction velocity increases with shorter twitch duration[42], suggesting that the shorter T50 observed in the BRAF mutant hECTs may represent enhanced conduction throughout the tissue.”
BackgroundRole of Animal Models in HCM Research
Shephard, R., & Semsarian, C. (2009) · Journal of Cardiovascular Translational Research · doi:10.1007/s12265-009-9120-y · Cited by 14 · cited 1×
“Animal models for HCM have been invaluable in developing an understanding of the mechanisms governing the development of the disease [6,7].”
BackgroundSudden Cardiac Death in Young Athletes
Mortazavi, M. (2013) · Advances in Pediatrics · doi:10.1016/j.yapd.2013.04.015 · Cited by 12
Up-Regulation of hERG K+ Channels by B-RAF
Pakladok, T., Hosseinzadeh, Z., Almilaji, A., Lebedeva, A., Shumilina, E. V., Alesutan, I., & Lang, F. J. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087457 · Cited by 11
Cited by
Modeling human diseases with induced pluripotent stem cells: from 2D to 3D and beyond
Liu, C., Oikonomopoulos, A., Sayed, N., & Wu, J. C. (2018) · Development · doi:10.1242/dev.156166 · Cited by 267
“…tissue Dilated cardiomyopathy (Hinson et al., 2015; Tiburcy et al., 2017), heart failure (Tiburcy et al., 2017), hypertrophic cardiomyopathy (Cashman et al., 2016) Organ-on-chip Barth syndrome-associated cardiomyopathy (Wang et al., 2014) Skeletal muscle Engineered tissue Muscular dystrophy…”
BackgroundGoldfracht, I., Protze, S., Shiti, A., Setter, N., Gruber, A., Shaheen, N., Nartiss, Y., Keller, G., & Gepstein, L. (2020) · Nature Communications · doi:10.1038/s41467-019-13868-x · Cited by 263
The RASopathy Family: Consequences of Germline Activation of the RAS/MAPK Pathway
Tajan, M., Paccoud, R., Branka, S., Edouard, T., & Yart, A. (2018) · Endocrine Reviews · doi:10.1210/er.2017-00232 · Cited by 237
Goldfracht, I., Efraim, Y., Shinnawi, R., Kovalev, E., Huber, I., Gepstein, A., Arbel, G., Shaheen, N., Tiburcy, M., Zimmermann, W. H., et al. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.05.016 · Cited by 222
Smith, A. S. T., Macadangdang, J. R., Leung, W. W., Laflamme, M. A., & Kim, D. (2016) · Biotechnology Advances · doi:10.1016/j.biotechadv.2016.12.002 · Cited by 169
“Reprinted with permission (Cashman et al., 2016).”
Metadata
- Authors
- Cashman, T. J., Josowitz, R., Johnson, B. V., Gelb, B. D., & Costa, K. D.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Costa, Kevin D.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-01-19
- Volume
- 11
- Issue
- 1
- Pages
- e0146697
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4718533
- OpenAlex
- W2372676601
- Cited by
- 101
- References
- 43
- Citations by year
- 2026: 5 · 2025: 6 · 2024: 13 · 2023: 13 · 2022: 10 · 2021: 13 · 2020: 11 · 2019: 13 · 2018: 8 · 2017: 6 · 2016: 3
- FWCI
- 5.20
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- American Heart Association (12PRE12060254)
- Icahn School of Medicine at Mount Sinai
- National Institutes of Health
- National Heart, Lung, and Blood Institute (HL113499, R01HL113499, F30HL118923, HHSN268201000045C)
- National Institute of General Medical Sciences (T32GM008553)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD075735)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- hypertrophic cardiomyopathy, BRAF mutation, cardiofaciocutaneous syndrome, RASopathies, RAS/MAPK pathway, induced pluripotent stem cells, cardiomyocyte differentiation, stromal co-culture, twitch force, atrial natriuretic peptide, arrhythmogenic substrate, passive stiffness, disease modeling, sudden cardiac death
- MeSH terms
- Cardiomyopathy, Hypertrophic, Cell Differentiation, Cells, Cultured, Humans, Mutation, Myocardial Contraction, Atrial Natriuretic Factor, Tissue Engineering, Myocytes, Cardiac, Proto-Oncogene Proteins B-raf, Induced Pluripotent Stem Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.